Pietro L Laforgia
Overview
Explore the profile of Pietro L Laforgia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paradies V, Smits P, Maurina M, Laforgia P, van der Linden M, Damman P, et al.
EuroIntervention
. 2024 Oct;
20(19):e1227-e1236.
PMID: 39374091
Background: Intracoronary continuous thermodilution is a novel technique to quantify absolute true coronary flow and microvascular resistance. However, few data are available in patients with angina with non-obstructive coronary arteries...
2.
Gallo M, Sa M, Doulamis I, Hussein N, Laforgia P, Kampaktsis P, et al.
Expert Rev Med Devices
. 2021 Jun;
18(7):597-608.
PMID: 34080501
: Aortic and mitral bioprosthesis are the gold standard treatment to replace a pathological native valve. However, bioprostheses are prone to structural valve degeneration, resulting in limited long-term durability. During...
3.
Sa M, Simonato M, Van den Eynde J, Cavalcanti L, Alsagheir A, Tzani A, et al.
Catheter Cardiovasc Interv
. 2021 Feb;
98(5):E746-E757.
PMID: 33555107
Background: There is a rising trend for transcatheter aortic valve implantation (TAVI) in bicuspid aortic stenosis patients. Data on the use of self-expandable (SEV) vs. balloon-expandable (BEV) valves in these...
4.
Sa M, Van den Eynde J, Simonato M, Cavalcanti L, Doulamis I, Weixler V, et al.
JACC Cardiovasc Interv
. 2021 Jan;
14(2):211-220.
PMID: 33478639
Objectives: The aim of this study was to evaluate early results of valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) versus redo surgical aortic valve replacement (SAVR) for structural valve degeneration...
5.
Gallo M, Guariento A, Laforgia P, Blitzer D, Doulamis I, Putzu A
J Thorac Cardiovasc Surg
. 2020 Jul;
160(4):e181-e182.
PMID: 32718704
No abstract available.
6.
Gallo M, Blitzer D, Laforgia P, Doulamis I, Perrin N, Bortolussi G, et al.
J Thorac Cardiovasc Surg
. 2020 Jun;
163(1):94-105.e15.
PMID: 32499076
Background: The optimal revascularization strategy for patients with left main coronary artery disease is still controversial. This is systematic review and meta-analysis aims to evaluate the outcomes of percutaneous coronary...
7.
Smits P, Laforgia P, Abdel-Wahab M, Neumann F, Richardt G, Klerk B, et al.
EuroIntervention
. 2020 Apr;
16(3):225-232.
PMID: 32250250
Aims: The Compare-Acute trial showed superiority of fractional flow reserve (FFR)-guided acute complete revascularisation compared to culprit-only treatment in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD)...
8.
Durante A, Laforgia P, Aurelio A, Foglia-Manzillo G, Bronzato S, Santarone M, et al.
Cardiol Young
. 2014 Sep;
25(3):408-23.
PMID: 25230132
Sudden cardiac death in the young is a relatively uncommon but marked event usually related to congenital diseases or anomalies. Despite the prevalence of each condition being variable, most common...